BioCryst Pharmaceuticals, Inc.

What they do

BioCryst discovers, develops and commercializes small-molecule and protein therapeutics aimed at rare diseases, using structure-guided drug design and external business development. Its lead product, ORLADEYO (berotralstat), is an approved once-daily oral capsule and oral pellet treatment for hereditary angioedema in the U.S. and multiple global markets. The company also sells injectable peramivir antivirals (RAPIVAB, RAPIACTA, PERAMIFLU) in the U.S., Australia, Canada, Japan, Taiwan and Korea, and is developing navenibart, BCX17725, avoralstat and STAR-0310. It commercializes ORLADEYO directly in the U.S. and through partners including Torii in Japan and Neopharmed Gentili in Europe.

Revenue drivers

• ORLADEYO (berotralstat) — Approved oral HAE therapy and the largest contributor: $158.2 million of net revenue in Q2 2026, versus $218.3 million of total revenue for the quarter. Full-year 2026 guidance is $625–645 million.
• Navenibart European licensing (Neopharmed Gentili) — Upfront consideration of $70.0 million, with up to $275.0 million in future regulatory and sales milestones plus tiered royalties of 18%–30% on net sales. $55.7 million was recognized in Q2 2026, with the balance recognized over the next few years.
• Peramivir antivirals — RAPIVAB, RAPIACTA and PERAMIFLU are approved in the U.S., Australia, Canada, Japan, Taiwan and Korea and are commercialized largely through partners such as Shionogi and Green Cross.

Recent performance

Q2 2026 total revenue was $218.3 million, up 34% year over year, including ORLADEYO net revenue of $158.2 million, up 1% year over year and up 10% excluding European revenue. The quarter produced operating profit of $98.5 million and non-GAAP operating profit of $113.2 million. Full-year 2025 revenue was $874.8 million with net income of $263.9 million and diluted EPS of $1.21, the first annual GAAP profit; operating cash flow was $347.4 million. At June 30, 2026, cash and equivalents were $155.0 million, total liabilities $1.01 billion and shareholder equity negative $454.3 million.

Strategy

Management is prioritizing external innovation over internal discovery: in June 2026 BioCryst announced discontinuation of its internal discovery programs and closure of its Birmingham facility by the end of 2026. It continues to commercialize ORLADEYO, including the newly launched oral pellet formulation for pediatric patients, and has engaged CareMed as its sole-source specialty pharmacy starting in Q3 2026. Pipeline priorities are navenibart, with pivotal ALPHA-ORBIT enrollment completed in June, and BCX17725 in Netherton syndrome, where Phase 1 Part 4 data are expected by year-end 2026. The company also monetizes non-U.S. rights through partners, as with the Neopharmed Gentili navenibart license in Europe.

Risks

• No sustained profitability yet — The 10-K states BioCryst achieved annual GAAP net income for the first time in 2025 but has not achieved sustained profitability, which depends on commercial execution and forecast accuracy.
• Negative shareholder equity and debt load — At June 30, 2026, shareholder equity was negative $454.3 million against total liabilities of $1.01 billion, including $395.4 million of long-term debt under the Blackstone Loan Agreement.
• Royalty obligations reduce product economics — The 10-K notes that obligations to pay RPI and OMERS royalties on certain ORLADEYO revenues under the Royalty Purchase Agreements may reduce product profitability.
• Pipeline and launch execution risk — Navenibart top-line results are not expected until Q3 2027, BCX17725 data are pending, and the pediatric pellet launch and CareMed pharmacy transition carry execution risk.

Outlook

Management maintained full-year 2026 ORLADEYO revenue guidance of $625–645 million and raised total revenue guidance to $690–715 million. It expects navenibart top-line results for both every-three-month and every-six-month dosing in Q3 2027, and BCX17725 Phase 1 Part 4 data by the end of 2026. The company says it remains focused on cost discipline and positive free cash flow while shifting toward external innovation.